Application of CRISPR/Cas9-based mutant enrichment technique to improve the clinical sensitivity of plasma EGFR testing in patients with non-small cell lung cancer

BACKGROUND: Approximately 50%–60% of secondary resistance to primary EGFR- tyrosine kinase inhibitors (TKI) therapy is caused by acquired p.Thr790Met (T790M) mutation; however, highly fragmented, low-quantity circulating tumor DNA is an obstacle for detecting mutations. Therefore, more sensitive mut...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Boyeon, Kim, Yoonjung, Shin, Saeam, Lee, Seung-Tae, Cho, Jae Yong, Lee, Kyung-A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845274/
https://www.ncbi.nlm.nih.gov/pubmed/35168603
http://dx.doi.org/10.1186/s12935-022-02504-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845274/
https://www.ncbi.nlm.nih.gov/pubmed/35168603
http://dx.doi.org/10.1186/s12935-022-02504-2

Ejemplares similares